Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio announced that China’s National Medical Products Administration has approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who either have or have not been previously treated with ROS1 tyrosine kinase inhibitors.